Adaptive Biotechnologies Executes Lease for New 100,000 Square Foot Corporate Headquarters, Tripling its Footprint in Seattle’s Growing Biotech Hub

NEXT STORY
New York Psychiatrist, Dr. Aleksandra Krunic, Introduces Groundbreaking FDA-Cleared Helmet to Treat Obsessive-Compulsive Disorder (OCD)
PREV STORY
Assembly Biosciences Announces Appointment of John McHutchison, AO, MD, as President and Chief Executive Officer
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Prothena Reports Results of Phase 1 Single Ascending Dose Study of PRX003, Demonstrating Target Engagement of the Novel Anti-MCAM Antibody for Inflammatory Diseases

All doses of PRX003 found to be safe and well tolerated, meeting the primary ...

author_avatar
NASDAQ Market News

Achillion Announces Appointments of Martha Manning as General Counsel and Amy Jennings as Head of Regulatory Affairs

NEW HAVEN, Conn., Feb. 03, 2016 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today ...

author_avatar
NASDAQ Market News

Chicago-based Psychiatrist, Dr. Fabian Carbonell, Debuts Innovative FDA-Cleared Treatment for Major Depressive Disorder (MDD) and Obsessive-Compulsive Disorder (OCD)

author_avatar
NASDAQ Market News